C4U Co., Ltd. announced that it has received ¥930 million in funding from TAUNS Laboratories, INC., DCI Partners Co., Ltd., Nissay Capital Co., Ltd., Mizuho Capital Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., M3, Inc., Investment Arm
August 03, 2021
Share
C4U Co., Ltd. announced that it has received ¥930 million in an equity round of funding led by Daiwa Taiwan-Japan BioVenture Investment Limited Partnership II, a fund managed by DCI Partners Co., Ltd. on August 4, 2021. The round is raised through a third-party allocation of new shares. The transaction also included participation from 1p1y Fund, a fund managed by M3, Inc., Nissay Capital No. 11 Investment Limited Partnership, a fund managed by Nissay Capital Co., Ltd., Mizuho Life Science No. 1 Fund, a fund managed by Mizuho Capital Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd. and Tauns Laboratories,Inc..
Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.) specializes in development, manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceuticals (92.9%): for cardiovascular, gastrointestinal and infectious diseases, central nervous systems disorders and allergies treatment;
- other (7.1%): veterinary drugs, food additives, industrial chemical products, etc.
Net sales are distributed geographically as follows: Japan (39.8%), the United States (50.4%), North America (0.9%) and other (8.9%).
C4U Co., Ltd. announced that it has received ¥930 million in funding from TAUNS Laboratories, INC., DCI Partners Co., Ltd., Nissay Capital Co., Ltd., Mizuho Capital Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., M3, Inc., Investment Arm
SUMITOMO PHARMA CO., LTD. 
